US 2020/0399353 A1 · ANTI-ANNEXIN A2 MONOCLONAL ANTIBODIES

Abstract

The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GYSITSGYSWH; a VHCDR2 having the amino acid sequence YIHYSGSTKYNPSLKS and a VHCDR3 having the amino acid sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLYSNDQKNYLA, a VLCDR2 having the amino acid sequence WASIRES, and a VLCDR3 having the amino acid sequence QQYYIYPLT. The present invention also relates to an antigen-binding protein, or an antigen-binding fragment thereof, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence VYSITSGYSWH; a VHCDR2 having the amino acid sequence YIHYSGSTKYNPSLKS, and a VHCDR3 having the amino acid sequence GTDNAVDY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLYSSNQKNYLA, a VLCDR2 having the amino acid sequence WAS SRES, and a VLCDR3 having the amino acid sequence QQYYIYPLT. Compositions comprising the antigen-binding protein, or antigen-binding fragment thereof, methods of use of the antigen-binding protein, or antigen-binding fragment thereof and kits comprising the antigen-binding protein, or antigen-binding fragment thereof are also provided.

Claims20

Dependent claims

1-62. (canceled)

A method of treating or preventing cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an antigen-binding protein or an antigen-binding fragment thereof, or a composition comprising a physiologically acceptable carrier and a therapeutically effective amount of an antigen-binding protein or an antigen-binding fragment thereof, wherein said antigen-binding protein or antigen-binding fragment thereof binds to an N-linked glycan on annexin A2 (ANXA2).

A method for detecting cancer in a subject or identifying a subject susceptible to cancer, comprising:

obtaining a sample from the subject;
contacting the sample with an antigen-binding protein, or an antigen-binding fragment thereof, wherein said antigen-binding protein or antigen-binding fragment thereof binds to an N-linked glycan on annexin A2 (ANXA2);
detecting the binding of the antigen-binding protein or antigen-binding fragment thereof in the sample;
correlating the binding with a level of binding in a control sample to determine the level of binding in the sample, wherein an increase in the level of binding in the sample relative to the control sample is indicative of cancer or identifies a subject susceptible to cancer.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

16/848,828Filed 14 Apr 2020

Priority

SG 10201606178X26 Jul 2016

Published

24 Dec 2020

Term ends

Not estimatedThe source records don’t support an estimate.

Classification37 codes

C07K 16/18
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material from animals or humans
A61K 31/282
Compounds containing heavy metals: platinum compounds
A61K 31/337
Having oxygen as the only ring hetero atom, e.g. fungichromin: having four-membered rings, e.g. taxol
A61K 31/5377
1,4-Oxazines, e.g. morpholine: not condensed and containing further heterocyclic rings, e.g. timolol

Anti-annexin a2 monoclonal antibodies

Life of this patent

Anti-annexin a2 monoclonal antibodies

Life of this patent

Abstract

Claims20